Jazz Pharmaceuticals (JAZZ) posted Q1 non-GAAP earnings late Tuesday of $1.68 per diluted share, down from $2.63 a year ago.
Analysts polled by FactSet expected $4.66.
Revenue for the quarter ended March 31 was $897.8 million, down from $902.0 million a year earlier.
Analysts surveyed by FactSet expected $983.8 million.
For 2025, the company said it now expects adjusted EPS of $4.00 to $5.60 on revenue of $4.15 billion to $4.40 billion.
It forecast EPS of $22.50 to $24.00 previously. Analysts expected $23.22 and $4.29 billion, respectively.
Shares of Jazz were down about 6.5% in after-hours activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。